Skip to content

A&O advises Ipsen in relation to the sale of its consumer healthcare business to Mayoly Spindler

Related people
Castagnede Marc
Marc Castagnede

Partner

Paris

View profile →

Image of Romy Richter
Romy Richter

Partner

Paris

View profile →

Moreau Frederic
Frederic Moreau

Partner

Paris

View profile →

Image of Olivier Picquerey
Olivier Picquerey

Partner

Paris

View profile →

Ninane Florence
Florence Ninane

Partner

Paris

View profile →

Valois Guillaume
Guillaume Valois

Partner

Paris

View profile →

Ekrami Susan
Susan Ekrami

Counsel

Paris

View profile →

Ancenys Laurie-Anne
Laurie-Anne Ancenys

Counsel

Paris

View profile →

Lamblin Luc
Luc Lamblin

Counsel

Paris

View profile →

Del Valle Charles-Antoine
Charles Del Valle

Counsel

Paris

View profile →

Sauzay Arthur
Arthur Sauzay

Counsel

Paris

View profile →

Pauline Regnier

Senior Associate

Paris

View profile →

Antoine Messent

Associate

Paris

View profile →

Image of Hovig Cancioglu
Hovig Cancioglu

Associate

Paris

View profile →

Image of Noemie Bomble
Noemie Bomble

Associate

Paris

View profile →

Image of Juliette Olliveaud
Juliette Olliveaud

Associate

Paris

View profile →

Marie Coussi

Associate

Paris

View profile →

Marianne Delassaussé

Peerpoint Consultant

Paris

View profile →

Press contacts

For media enquiries relating to this topic, please contact:

Amelie Gillot

Communications officer

Paris

View profile →

15 February 2022

Allen & Overy Paris has advised Ipsen on its entry into exclusive negotiations with the pharmaceutical laboratory Mayoly Spindler in relation to the divestment of its consumer healthcare (CHC) business, which includes the drugs Smecta®, Forlax®, Tanakan®, Fortrans® and various production sites.

The combination of Ipsen’s and Mayoly Spindler’s respective CHC businesses will create a global consumer healthcare platform with a critical size and the capacity to support its growth. Capza and Caravelle, two financial investors, are supporting Mayoly Spindler and will provide part of the financing required to complete this transaction, by acquiring a minority stake in the new entity.

The transaction will be submitted to the relevant employee representative bodies of Ipsen. The closing of the transaction is expected before the end of the third quarter of 2022 upon completion of regulatory and antitrust filings and customary conditions precedent. 

The Allen & Overy team is led by Marc Castagnède (Partner) and Romy Richter (Partner) with Frédéric Moreau (Partner), with support from Pauline Régnier (Associate) and Antoine Messent (Associate).

The team also included Olivier Picquerey (Partner), Susan Ekrami (Counsel) and Hovig Cancioglu (Associate) on employment law aspects, Florence Ninane (Partner) and Noémie Bomble (Associate) on antitrust aspects, Laurie-Anne Ancenys (Counsel ) and Juliette Olliveaud (Associate) on IT aspects and transitional services, Luc Lamblin (Counsel) on aspects related to the control of foreign investments, Guillaume Valois (Partner) and Charles del Valle (Counsel) on tax aspects, Arthur Sauzay (Counsel) and Marie Coussi (Associate) on public and environmental law aspects, Marianne Delassaussé (Senior Consultant) on intellectual property aspects.